Rasmussen L H, Husted S E, Clemmensen P M, Gøtzsche C O, Helqvist S, Kristensen S D, Pedersen K E, Rasmussen K, Rasmussen S
Hjertecentret, kardiologisk afdeling S, Aalborg Sygehus Syd.
Ugeskr Laeger. 2000 Oct 30;162(44):5944-7.
Platelet activation plays a major role in the pathophysiology of acute coronary syndromes (ACS), and inhibition of platelet function is the basic pharmacological treatment of ACS. Platelet membrane glycoprotein IIb/IIIa inhibitors, a new class of potent antiplatelet agents, have been used in the treatment of ACS, as well as in the prevention of complications after percutaneous coronary interventions. The aim of this article is to describe the potential possibilities of platelet inhibition and to review the pharmacology of glycoprotein IIb/IIIa inhibitors, the results of the clinical trials with these agents, and their current use in the pharmacological treatment of ACS and in relation to percutaneous coronary intervention.
血小板活化在急性冠脉综合征（ACS）的病理生理学中起主要作用，抑制血小板功能是ACS的基本药物治疗方法。血小板膜糖蛋白IIb/IIIa抑制剂是一类新型强效抗血小板药物，已用于ACS的治疗以及经皮冠状动脉介入治疗后并发症的预防。本文旨在描述血小板抑制的潜在可能性，并综述糖蛋白IIb/IIIa抑制剂的药理学、这些药物的临床试验结果以及它们在ACS药物治疗中的当前应用情况以及与经皮冠状动脉介入治疗的关系。
